{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:55:21Z","timestamp":1791568521522,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2005,2,9]],"date-time":"2005-02-09T00:00:00Z","timestamp":1107907200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2005,3]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>The combination of ephedrine and caffeine has been used in herbal products for weight loss and athletic performance\u2010enhancement, but the pharmacokinetic profiles of these compounds have not been well characterized. This study aimed to develop a mechanistic model describing ephedrine, norephedrine, and caffeine pharmacokinetics and their interactions in healthy subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The pharmacokinetic model was developed based on the simultaneous modelling using plasma samples gathered from two clinical trials. The treatments consisted of single\u2010doses of pharmaceutical caffeine and ephedrine, given alone or together, and an herbal formulation containing both caffeine and ephedrine. We used a mixed\u2010effect statistical model and the program NONMEM to take account of intersubject variability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Three hundred and seventy\u2010nine ephedrine, 352 norephedrine, 417 caffeine plasma concentrations and 40 ephedrine urine concentrations were obtained from 24 subjects. A one\u2010compartment model with first\u2010order absorption described the caffeine data. Caffeine clearance was 0.083\u2003l\u2003min<jats:sup>\u22121<\/jats:sup> (CV 38%) and decreased to 0.038\u2003l min<jats:sup>\u22121<\/jats:sup> in presence of oral contraceptive therapy, its volume of distribution was 38.6 l (CV 20%) and its absorption rate constant was 0.064 l\u2003min<jats:sup>\u22121<\/jats:sup> (CV 50%). A four\u2010compartment model described the pharmocokinetics of ephedrine and norephedrine. Ephedrine was eliminated mostly renally, with a clearance of 0.34\u2003l\u2003min<jats:sup>\u22121<\/jats:sup> (CV 11%), and a volume of distribution of 181\u2003l (CV 19%). Nonlinearity in the conversion of ephedrine to norephedrine was observed. Different models showed that the simultaneous administration of caffeine, or the amount of caffeine in the absorption compartment, was associated with a slower rate of absorption of ephedrine. A 32% greater relative bioavailability of herbal compared with pharmaceutical ephedrine administration was observed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We describe a mechanistic model for ephedrine, norephedrine and caffeine pharmacokinetics and their interactions. The relative bioavailability of ephedrine differed between the herbal supplement compared with the pharmaceutical formulation. Concomitant ingestion of caffeine slowed the absorption rate of ephedrine, which is mainly related to the amount of the former in the absorption compartment. A saturable process appears to be involved in the metabolism of ephedrine to norephedrine.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2005.02254.x","type":"journal-article","created":{"date-parts":[[2005,3,7]],"date-time":"2005-03-07T09:32:29Z","timestamp":1110187949000},"page":"335-345","source":"Crossref","is-referenced-by-count":31,"title":["Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects"],"prefix":"10.1111","volume":"59","author":[{"given":"C.","family":"Csajka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. A.","family":"Haller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. L.","family":"Benowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Verotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2005,2,9]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.1996.03540210019010","article-title":"Adverse events associated with ephedrine\u2010containing products\u2013Texas, December 1993\u2013September 1995","volume":"276","author":"Centers for Disease Control and Prevention.","year":"1996","journal-title":"JAMA"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.7.1313"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012213432502"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199710000-00025"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.68.1.112"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1081\/CLT-120025350"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2003.08.012"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0736-4679(98)00194-2"},{"key":"e_1_2_6_10_2","first-page":"6787","article-title":"Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk","volume":"69","author":"US Food and drug administration.","year":"2004","journal-title":"Fed Regist"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600571122"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600601107"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1976.tb00579.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1067\/mcp.2002.124523"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2003.11.375"},{"key":"e_1_2_6_16_2","first-page":"95","article-title":"Population pharmacokinetic analysis of ephedrine in kampo prescriptions: a study in healthy volunteers and clinical use of the pharmacokinetic results","volume":"20","author":"Yafune A","year":"2001","journal-title":"Int J Clin Pharm Res"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.12.1537"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0026-0495(91)90117-F"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801539"},{"key":"e_1_2_6_20_2","volume-title":"The Mathematical Modeling of Metabolic and Endocrine Systems","author":"Carlson ER","year":"1983"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.155"},{"key":"e_1_2_6_22_2","unstructured":"http:\/\/www.globomax.net\/products\/nonmen.cfm."},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1109\/TAC.1974.1100705"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1987.126"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1990.66"},{"key":"e_1_2_6_26_2","first-page":"43","article-title":"Caffeine as an analgesic adjuvant. a review of pharmacology and mechanisms of action","volume":"45","author":"Sawynok J","year":"1993","journal-title":"Pharmacol Rev"},{"key":"e_1_2_6_27_2","first-page":"603","article-title":"Imparied elimination of caffeine by oral contraceptive steroids","volume":"95","author":"Patwardhan RV","year":"1980","journal-title":"J Laboratory clin Medical"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00614017"},{"key":"e_1_2_6_29_2","first-page":"37","article-title":"Biotransformation of D (\u2013)\u2010ephedrine and L (+) \u2010ephedrine in the rabbit, in vivo and in vitro","volume":"5","author":"Feller DR","year":"1977","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007691-199808000-00015"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1997.tb04769.x"},{"key":"e_1_2_6_32_2","first-page":"15","volume-title":"Clinical Pharmacokinetics Concepts and Applications","author":"Rowland M","year":"1994"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655299750025525"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-277X.2001.00290.x"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2005.02254.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2005.02254.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T00:23:02Z","timestamp":1697242982000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2005.02254.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["10.1111\/j.1365-2125.2005.02254.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2005.02254.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,2,9]]}}}